Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fasting at night may cut cancer risk in people with blood disorder precursors

NCT ID NCT05565638

Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether fasting for at least 14 hours each night could help overweight people with early blood cancer conditions (MGUS, smoldering myeloma) lose weight and possibly lower their cancer risk. Twenty-three participants were randomly assigned to either the fasting program or a healthy lifestyle education group for 4 months. The main goal was to see changes in body composition, with secondary measures of blood markers related to cancer progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
prolonged nightly fasting (behavioral intervention)
What this could lead to
If this works, it could point toward a simple lifestyle change—extending the nightly fast—to help prevent blood cancer in people with early warning signs.
What could go wrong
This is a very small, early study (23 participants) testing weight loss, not cancer directly. The fasting intervention may be hard to stick with long-term, and any cancer benefit is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

23 people

The number who actually took part.

Started

Mar 2023

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * BMI \>= 25 kg/m2 * Documented diagnosis of MGUS or Smoldering MM(SMM) or Smoldering Waldenstrom Macroglobulinemia(WM) via EMR review. \*note: please review case with PI or treating MD if diagnosis is uncertain. * At least 18 years of age * Currently fasting for \<14 hours per night, as assessed using 24-hour food recalls * Owns a cell phone and is comfortable sending and receiving text messages * Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: * Diagnosis of overt MM or WM * Patients diagnosed with another malignancy requiring active therapy * Clinical diagnosis of diabetes, which may increase the risk of hypoglycemia with a prolonged fast. Note: patients with diabetes may enroll with consent from MD that manages their clinical care. * Any other condition that, in the investigator's judgment, would contraindicate prolonged nightly fasting or otherwise interfere with participation in the trial, including night shift work, night eating syndrome, taking weight loss medication, or participation in another weight loss program

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cancer prevention are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Fasting monoclonal gammopathy of uncertain significance Smoldering Multiple Myeloma smoldering plasma cell myeloma Waldenstrom macroglobulinemia Weight Loss plasma cell myeloma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cancer prevention Fasting MGUS Multiple myeloma Smoldering Waldenstrom macroglobulinemia(WM) Weight loss

Contacts and locations

Locations

  • Dana Farber Cancer Institute

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.